A share price of Marinus Pharmaceuticals Inc [MRNS] is currently trading at $9.39, up 4.92%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The MRNS shares have gain 6.10% over the last week, with a monthly amount drifted -6.19%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 5, March 2024, Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results. In a post published today on Yahoo Finance, Phase 3 RAISE trial interim analysis enrollment target achieved with Data Monitoring Committee (DMC) review scheduled and topline results expected in first half of Q2 2024.
From an analyst’s perspective:
Marinus Pharmaceuticals Inc [NASDAQ: MRNS] stock has seen the most recent analyst activity on August 11, 2023, when Oppenheimer downgraded its rating to a Perform and also revised its price target to $9 from $14. Previously, RBC Capital Mkts started tracking the stock with Outperform rating on January 20, 2023, and set its price target to $23. On September 30, 2020, Truist initiated with a Buy rating and assigned a price target of $35 on the stock. H.C. Wainwright reiterated its Buy rating and increased its price target to $9 on July 01, 2020. Cowen initiated its recommendation with a Outperform. Craig Hallum started tracking with a Buy rating for this stock on April 09, 2020, and assigned it a price target of $4.50. In a note dated December 20, 2019, Oppenheimer initiated an Outperform rating.
Marinus Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $5.57 and $11.26. Marinus Pharmaceuticals Inc [NASDAQ: MRNS] shares were valued at $9.39 at the most recent close of the market.
Analyzing the MRNS fundamentals
Trailing Twelve Months sales for Marinus Pharmaceuticals Inc [NASDAQ:MRNS] were 30.99M which represents 0.39% growth. Gross Profit Margin for this corporation currently stands at 0.93% with Operating Profit Margin at -4.24%, Pretax Profit Margin comes in at -4.61%, and Net Profit Margin reading is -4.56%. To continue investigating profitability, this company’s Return on Assets is posted at -0.83, Equity is -2.64 and Total Capital is -1.01. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of6.54.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 8.96 points at the first support level, and at 8.53 for the second support level. However, for the 1st resistance point, the stock is sitting at 9.75, and for the 2nd resistance point, it is at 10.12.
Marinus Pharmaceuticals Inc [MRNS] reported earnings per share of -$0.74 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.62/share, meaning a difference of -$0.12 and a surprise factor of -19.40%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.61 per share as compared to estimates of -$0.66 per share, a difference of $0.05 representing a surprise of 7.60%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Marinus Pharmaceuticals Inc [NASDAQ:MRNS] is 4.07. Also, the Quick Ratio is 4.01, while the Cash Ratio stands at 2.97. Considering the valuation of this stock, the price to sales ratio is 16.56, the price to book ratio is 30.57.
Transactions by insiders
Recent insider trading involved Shafer Christina, CHIEF COMMERCIAL OFFICER, that happened on Feb 20 ’24 when 2153.0 shares were sold. SVP, GEN. COUNSEL & CORP. SEC., MANNING MARTHA E completed a deal on Feb 20 ’24 to sell 1894.0 shares. Meanwhile, CHAIRMAN AND CEO Braunstein Scott sold 11850.0 shares on Feb 16 ’24.
